This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rosin, M. P. Articles by Zhang, L. Search for Related Content PubMed PubMed Citation Articles by Rosin, M. P. Articles by Zhang, L.

3p14 and 9p21 Loss Is a Simple Tool for Predicting Second Oral Malignancy at Previously Treated Oral Cancer Sites¹

British Columbia Cancer Research Centre, Vancouver, British Columbia, V5Z 1L3 [M. P. R., W. L. L., N. D. L.]; School of Kinesiology, Simon Fraser University, Burnaby, British Columbia, V5A 1S6 [M. P. R., C. P., R. J. L., T. Z.]; and Faculty of Dentistry, the University of British Columbia, Vancouver, British Columbia, V6T 1Z3 [C. P., R. P., L. Z.] Canada

Treatment induces reactive changes that often resemble low-grade dysplasia at former oralcancer sites, complicating histopathological assessment. We tested a set ofmicrosatellite markers shown previously to be predictive of progression for oral premalignant lesions for the ability to predict development of second oral malignancy (SOM). Sixty-eight oral leukoplakia at former cancer sites (with known outcome, 36 progressed to SOM) were evaluated for loss of heterozygosity at 19 loci on seven chromosome arms. 3p and/or 9p loss in these posttreatment leukoplakia was associated with a 26.3-fold increase in risk of developing SOM compared with those that retained both of these arms (P < 0.001), with 60% of cases with loss of heterozygosity developing SOM in 2 years. In contrast, histological diagnosis (moderate or severe dysplasia versus hyperplasia or mild dysplasia) had only a 1.7-fold increase in risk (P = 0.11). The identification of 3p and 9p loss in posttreatment lesions could serve as a simple and direct test for stratifying risk of SOM development.

This article has been cited by other articles:

				G. J. Kelloff, C. C. Sigman, and C. H. Contag Early Detection of Oral Neoplasia: Watching with New Eyes Cancer Prevention Research, May 1, 2009; 2(5): 405 - 408. [Full Text] [PDF]

				L. A. Kresty, S. R. Mallery, T. J. Knobloch, J. Li, M. Lloyd, B. C. Casto, and C. M. Weghorst Frequent Alterations of p16INK4a and p14ARF in Oral Proliferative Verrucous Leukoplakia Cancer Epidemiol. Biomarkers Prev., November 1, 2008; 17(11): 3179 - 3187. [Abstract] [Full Text] [PDF]

				I. F.L. Tsui, M. P. Rosin, L. Zhang, R. T. Ng, and W. L. Lam Multiple Aberrations of Chromosome 3p Detected in Oral Premalignant Lesions Cancer Prevention Research, November 1, 2008; 1(6): 424 - 429. [Abstract] [Full Text] [PDF]

				V. A. Papadimitrakopoulou, W. N. William Jr., A. J. Dannenberg, S. M. Lippman, J. J. Lee, F. G. Ondrey, D. E. Peterson, L. Feng, A. Atwell, A. K. El-Naggar, et al. Pilot Randomized Phase II Study of Celecoxib in Oral Premalignant Lesions Clin. Cancer Res., April 1, 2008; 14(7): 2095 - 2101. [Abstract] [Full Text] [PDF]

				W. N. William Jr. and V. A. Papadimitrakopoulou Identification of High-risk Cohorts for Head and Neck Cancer Prevention Based on Tissue Markers LOH and cyclin D1 ASCO Educational Book, January 1, 2008; 2008(1): 66 - 68. [Abstract] [Full Text] [PDF]

				S. M. Lippman and J. V. Heymach The Convergent Development of Molecular-Targeted Drugs for Cancer Treatment and Prevention Clin. Cancer Res., July 15, 2007; 13(14): 4035 - 4041. [Abstract] [Full Text] [PDF]

				C. F. Poh, L. Zhang, D. W. Anderson, J. S. Durham, P. M. Williams, R. W. Priddy, K. W. Berean, S. Ng, O. L. Tseng, C. MacAulay, et al. Fluorescence Visualization Detection of Field Alterations in Tumor Margins of Oral Cancer Patients. Clin. Cancer Res., November 15, 2006; 12(22): 6716 - 6722. [Abstract] [Full Text] [PDF]

				O. Kujan, R. Oliver, L. Roz, G. Sozzi, N. Ribeiro, R. Woodwards, N. Thakker, and P. Sloan Fragile Histidine Triad Expression in Oral Squamous Cell Carcinoma and Precursor Lesions. Clin. Cancer Res., November 15, 2006; 12(22): 6723 - 6729. [Abstract] [Full Text] [PDF]

				G. J. Kelloff, S. M. Lippman, A. J. Dannenberg, C. C. Sigman, H. L. Pearce, B. J. Reid, E. Szabo, V. C. Jordan, M. R. Spitz, G. B. Mills, et al. Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer--A Plan to Move Forward Clin. Cancer Res., June 15, 2006; 12(12): 3661 - 3697. [Abstract] [Full Text] [PDF]

				S. M. Lippman and J. J. Lee Reducing the "Risk" of Chemoprevention: Defining and Targeting High Risk--2005 AACR Cancer Research and Prevention Foundation Award Lecture. Cancer Res., March 15, 2006; 66(6): 2893 - 2903. [Abstract] [Full Text] [PDF]

				S.C. Reshmi and S.M. Gollin Chromosomal Instability in Oral Cancer Cells Journal of Dental Research, February 1, 2005; 84(2): 107 - 117. [Abstract] [Full Text] [PDF]

				U. Nair, H. Bartsch, and J. Nair Alert for an epidemic of oral cancer due to use of the betel quid substitutes gutkha and pan masala: a review of agents and causative mechanisms Mutagenesis, July 1, 2004; 19(4): 251 - 262. [Abstract] [Full Text] [PDF]

				B. J. M. Braakhuis, C. R. Leemans, R. H. Brakenhoff, M. P. Rosin, W. L. Lam, and L. Zhang Correspondence re: M. P. Rosin et al., 3p14 and 9p21 Loss Is a Simple Tool for Predicting Second Oral Malignancy at Previously Treated Oral Cancer Sites. Cancer Res., 62: 6447-6450, 2002. Cancer Res., August 15, 2003; 63(16): 5167 - 5169. [Full Text] [PDF]